KYORIN Pharmaceutical Co., Ltd. (TYO:4569)
Japan · Delayed Price · Currency is JPY 1,523.00
-2.00 (-0.13%)
Jul 30, 2025, 3:30 PM JST
KYORIN Pharmaceutical Revenue
In the fiscal year ending March 31, 2025, KYORIN Pharmaceutical had annual revenue of 130.09B JPY with 8.83% growth. KYORIN Pharmaceutical had revenue of 40.80B in the quarter ending March 31, 2025, with 26.46% growth.
Revenue
130.09B
Revenue Growth
+8.83%
P/S Ratio
0.67
Revenue / Employee
65.11M
Employees
1,998
Market Cap
87.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 130.09B | 10.56B | 8.83% |
| Mar 31, 2024 | 119.53B | 6.26B | 5.53% |
| Mar 31, 2023 | 113.27B | 7.74B | 7.33% |
| Mar 31, 2022 | 105.53B | 2.63B | 2.56% |
| Mar 31, 2021 | 102.90B | -7.08B | -6.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 866.03B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Shionogi & | 438.27B |